Spero Therapeutics announced it has extended its cash runway into the second half of 2029 following the closing of a $105 million nondilutive, nonrecourse royalty financing with Healthcare Royalty. The notes carry a 10% annual interest rate and a 9-year maturity, and after repayment Spero retains 35% of additional GSK milestone and royalty proceeds. The company also highlighted the FDA approval of Utebzi, the first and only oral carbapenem antibiotic approved in the United States, with GSK expecting U.S. availability in the second half of this year. Additionally, Spero in-licensed SP001 from Innovent Biologics for an estimated $1.1 billion in total contingent deal value, gaining exclusive worldwide rights excluding Greater China, and plans to advance SP001 in IgG4-related disease with a Phase II trial expected to begin in the second quarter of 2027. For the second quarter of 2026, Spero reported no revenue compared with $14.2 million a year earlier, research and development expenses of $3.4 million versus $10.7 million, and a net loss of $9.6 million, or $0.16 per share.
Innovent Biologics IncIn-licensed SP001 from Innovent for $1.1B total deal value
GSK plcGSK expects U.S. availability of Utebzi in H2 2025
Spero Therapeutics Inc$105M royalty financing extends cash runway to H2 2029
